Subscribe

Great Tree Pharmacy Co., Ltd. (6469.TWO)

TWD77.90 +0.60 (+0.78%)
TW TWO Healthcare Medical - Pharmaceuticals
Address No.143, Chengzhang Fourth Street 330
Taoyuan City, TW
CEO Ming-Lung Cheng
Website greattree.com.tw
IPO 2014-12-29
ISIN TW0006469000

Explore sections of this company profile

Description

Great Tree Pharmacy Co., Ltd. is a Taiwanese enterprise that operates an extensive chain of pharmacies throughout the island nation. These retail outlets offer a broad selection of goods, including prescription and over-the-counter medications, nutritional supplements, products specifically for mothers and infants, and various cosmetics. Beyond its retail presence, the company also delivers comprehensive medication procurement and coordination services to medical establishments such as individual clinics, shared outpatient facilities, and larger integrated healthcare networks. Furthermore, Great Tree Pharmacy acts as an agent for these same medical institutions, assisting them in the distribution and sale of popular health and wellness products sourced both domestically and internationally. Established in 2001, the company was initially named Tianjin Pharmaceutical Co., Ltd. before rebranding to its current designation. Its main corporate offices are located in Taoyuan City, Taiwan.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
TWD77.90 +0.60 (+0.78%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
600.1K
Beta
0.03
Float Shares
148.95M
Free Float %
99.5%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
+1.57% -6.07% -12.32% -19.27% -28.80% -23.93% -49.28% -68.74% +43.17% +357.58% +396.51%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
77.90
DCF (Unlevered) 335.44 +330.6%
DCF (Levered) 281.13 +260.9%

DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.

Ratings Trend (MoM) 0% Bullish
Rating 2026-05 Change
Strong Buy 0 0
Buy 0 0
Hold 1 0
Sell 1 0
Strong Sell 0 0
Quality scores
Altman Z-Score
2.53
Grey zone
Piotroski F-Score
5 / 9
Average
MOAT Score
6 / 10
Developing
Composite Rating
B+
Overall Score
3 / 5
Medium
DCF Score
5 / 5
High
ROE Score
4 / 5
High
ROA Score
4 / 5
High
D/E Score
1 / 5
Low
P/E Score
2 / 5
Medium
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
  • ✓
    Revenue growth Medical - Pharmaceuticals: +7.8%
    +9.4% ★ Q1'26: +3.7% (vs Q1'25)
  • ✗
    EPS growth Medical - Pharmaceuticals: +20.2%
    -23.6% Q1'26: -29.7% (vs Q1'25)
  • ✓
    FCF margin FCF growth · Medical - Pharmaceuticals: +43.3%
    +3.9% Q1'26: +8.3% (vs Q1'25)
  • ✗
    EBIT margin Medical - Pharmaceuticals: +6.8%
    +4.4% Q1'26: +2.7% (vs Q1'25)
  • ✗
    ROIC Medical - Pharmaceuticals: +6.1%
    +7.6% ★ Q1'26: +4.9% (vs Q1'25)
  • ✗
    Share dilution Medical - Pharmaceuticals: +0.0%
    +6.2% Q1'26: +7.5% (vs Q1'25)
  • ✗
    Debt / EBITDA Net debt/EBITDA · Medical - Pharmaceuticals: 0.21×
    4.13× Q1'26: 13.58× (vs Q1'25)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (0.03) × ERP
WACC = 60% × Ke + 40% × Kd (4.1%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Intrinsic value (base): 335.44 Current price: 77.90
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2016
actual 		Dec 2017
actual 		Dec 2018
actual 		Dec 2019
actual 		Dec 2021
actual 		Dec 2022
actual 		Dec 2023
actual 		Dec 2024
actual 		Dec 2025
actual 		Dec 2026
2 Rev. Ana.
1 EPS Ana. 		Dec 2027
2 Rev. Ana.
1 EPS Ana.
Revenue
2.80B
est: 2.82B (-0.7%)
3.62B
est: 2.82B (+28.4%)
4.90B
est: 3.67B (+33.6%)
6.60B
est: 4.81B (+37.2%)
11.28B
est: 11.31B (-0.3%)
14.56B
est: 14.58B (-0.1%)
16.14B
est: 16.69B (-3.3%)
17.27B
est: 17.28B (0.0%)
18.90B
est: 18.91B (-0.1%)
20.47B
20.38B – 20.56B
+8.3% YoY
22.45B
22.23B – 22.66B
+9.6% YoY
EBITDA
149.25M
est: 269.51M (-44.6%)
171.62M
est: 269.51M (-36.3%)
205.96M
est: 350.27M (-41.2%)
528.04M
est: 459.20M (+15.0%)
1.04B
est: 1.08B (-3.4%)
1.54B
est: 1.39B (+10.3%)
1.60B
est: 1.62B (-1.4%)
1.71B
est: 1.68B (+1.6%)
1.71B
est: 1.84B (-7.0%)
1.99B
1.98B – 2.00B
+8.3% YoY
2.18B
2.16B – 2.20B
+9.6% YoY
EBIT
100.73M
est: 142.40M (-29.3%)
108.29M
est: 142.40M (-24.0%)
138.27M
est: 185.07M (-25.3%)
198.04M
est: 242.63M (-18.4%)
544.80M
est: 570.71M (-4.5%)
928.18M
est: 735.47M (+26.2%)
899.32M
est: 881.76M (+2.0%)
905.67M
est: 912.66M (-0.8%)
829.81M
est: 999.23M (-17.0%)
1.08B
1.08B – 1.09B
+8.3% YoY
1.19B
1.17B – 1.20B
+9.6% YoY
Net Income
92.87M
est: 111.29M (-16.6%)
102.42M
est: 98.50M (+4.0%)
106.00M
est: 113.13M (-6.3%)
135.99M
est: 144.75M (-6.1%)
407.42M
est: 393.36M (+3.6%)
700.07M
est: 646.27M (+8.3%)
666.05M
est: 753.14M (-11.6%)
680.77M
est: 651.99M (+4.4%)
600.42M
est: 680.90M (-11.8%)
702.00M
619.92M – 705.50M
+3.1% YoY
723.61M
681.08M – 766.15M
+3.1% YoY
SGA
577.50M
est: 633.56M (-8.8%)
811.72M
est: 633.56M (+28.1%)
1.08B
est: 823.42M (+31.3%)
1.45B
est: 1.08B (+34.6%)
2.45B
est: 2.54B (-3.5%)
3.15B
est: 3.27B (-3.8%)
3.68B
est: 3.82B (-3.8%)
4.04B
est: 3.96B (+2.1%)
4.73B
est: 4.33B (+9.1%)
4.69B
4.67B – 4.71B
+8.3% YoY
5.14B
5.09B – 5.19B
+9.6% YoY
EPS
0.89
est: 0.82 (+9.2%)
0.97
est: 0.72 (+34.4%)
0.87
est: 0.83 (+5.0%)
1.38
est: 1.06 (+30.1%)
3.78
est: 2.88 (+31.2%)
6.39
est: 4.73 (+35.0%)
5.13
est: 5.19 (-1.2%)
5.17
est: 4.50 (+15.0%)
4.01
est: 4.70 (-14.6%)
4.57
4.27 – 4.87
-2.7% YoY
4.99
4.70 – 5.28
+9.2% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-12 B+ 3/5 5/5 4/5 4/5 1/5 2/5 2/5
2026-05-11 B+ 3/5 5/5 4/5 4/5 1/5 2/5 2/5
2026-05-08 B+ 3/5 5/5 4/5 4/5 1/5 3/5 2/5
2026-05-07 B+ 3/5 5/5 4/5 4/5 1/5 3/5 2/5
2026-05-06 B+ 3/5 5/5 4/5 4/5 1/5 3/5 2/5
2026-05-05 B+ 3/5 5/5 4/5 4/5 1/5 3/5 2/5
2026-05-04 B+ 3/5 5/5 4/5 4/5 1/5 3/5 2/5
2026-04-30 B+ 3/5 5/5 4/5 4/5 1/5 3/5 2/5
2026-04-29 B+ 3/5 5/5 4/5 4/5 1/5 3/5 2/5
2026-04-28 B+ 3/5 5/5 4/5 4/5 1/5 3/5 2/5
2026-04-27 B+ 3/5 5/5 4/5 4/5 1/5 3/5 2/5
2026-04-24 A- 4/5 5/5 4/5 5/5 1/5 3/5 2/5
2026-04-23 A- 4/5 5/5 4/5 5/5 1/5 3/5 2/5
2026-04-22 A- 4/5 5/5 4/5 5/5 1/5 3/5 2/5
2026-04-21 A- 4/5 5/5 4/5 5/5 1/5 3/5 2/5
2026-04-20 A- 4/5 5/5 4/5 5/5 1/5 3/5 2/5
2026-04-17 A- 4/5 5/5 4/5 5/5 1/5 3/5 2/5
2026-04-16 A- 4/5 5/5 4/5 5/5 1/5 3/5 2/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
1.22B
OE per share TTM
8.77
Owner's Yield
11.80%
Maintenance CapEx ratio
10.57%
Maint CapEx / Avg PPE
30.1%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock Held by 24 ETFs in our universe
# ETF Weight Est. AUM exposure TER
1 Avantis Emerging Markets Small Cap Equity ETF AVEE 0.01% 17.0K 0.42%
2 Dimensional Emerging Markets Sustainability Core 1 ETF DFSE 0.01% 31.9K 0.44%
3 Vanguard FTSE All-World ex-US Small-Cap ETF VSS 0.01% 727.0K 0.06%
4 Dimensional - Emerging Markets Value ETF DFEV 0.00% 98.1K 0.46%
5 Dimensional - Emerging Core Equity Market ETF DFAE 0.00% 205.2K 0.29%
6 Vanguard FTSE Emerging Markets Shares ETF VGE.AX 0.00% 22.3K 0.48%
7 Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO 0.00% 50.3K 0.26%
8 Vanguard FTSE Emerging Markets ETF VWO 0.00% 2.48M 0.06%
9 Vanguard ESG International Stock ETF VSGX 0.00% 59.8K 0.10%
10 Dimensional - Emerging Markets Core Equity 2 ETF DFEM 0.00% 75.9K 0.39%

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
1.86M
Shares Outstanding
149.70M

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Ming-Lung Cheng Chairman, Manager, Chief Executive Officer & President 8M male
Shan-Feng Lu Director & Deputy GM 5M male
Shih-Wei Yeh Assistant Manager of Product Purchase & Marketing Department and Director 3M male
Mei-Yun Liu Assistant Manager of the Administration Department — —
Shu-Yi Huang Chief Auditor — female
Shu-Yi Wu Accounting Supervisor & Assistant Manager of Finance Dept and Supervisor of Corporate Governance — female
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend yield history

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Medical - Pharmaceuticals